Text Size

Database of Interstitial Lung Diseases

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2005 by St. Antonius Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
St. Antonius Hospital
ClinicalTrials.gov Identifier:
NCT00267800
First received: December 19, 2005
Last updated: August 7, 2008
Last verified: December 2005
History of Changes
  Purpose

The cause of most interstitial lung diseases (ILDs) is still unknown. Further research, for example to determine predisposing genetic factors, is therefore needed. A database with relevant clinical data and DNA/serum samples of ILD patients could facilitate future research on the cause of ILDs.


Condition
Interstitial Lung Diseases

Study Type: Observational
Official Title: Registration of Clinical Data and DNA/Serum of Patients With Interstitial Lung Diseases (ILD)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by St. Antonius Hospital:

Estimated Enrollment: 100000
Study Start Date: January 2006
Detailed Description:

Protocol title: 'Registration of clinical data and DNA of patients with Interstitial Lung Disease (ILD)' Rationale: The etiopathogenesis of most Interstitial Lung Diseases (ILDs) is still unknown. Further research, e.g. to determine predisposing genetic factors, is therefore needed. A database with relevant clinical data and DNA/serum samples of ILD patients could facilitate future research on the etiopathogenesis of ILDs.

Objective: Availability of relevant clinical data and DNA/serum samples of ILD patients in a database. Those data can be used for future research.

Study design: A prospective observational study

Study population: Patients diagnosed with ILD attending the pulmonology department in participating hospitals.

Intervention: a blood sample is taken from each patient. Furthermore, additional information is collected from the medical file.

Main study parameters/endpoints: DNA and serum sample, demographic variables, medical information, occupational history and hobbies.

Nature and extent of the burden and risks associated with participation, group relatedness: two tubes of blood will be drawn from the patients. The risks of drawing blood from a vein are minimal.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of an ILD, as stated by the American Thoracic Society (ATS)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00267800

Locations
Netherlands
St. Antonius Hospital
Nieuwegein, Netherlands, 3435CM
UMC Utrecht
Utrecht, Netherlands, 3584 CX
Mesos Medisch Centrum
Utrecht, Netherlands, 3527 CE
Diakonessenhuis
Utrecht, Netherlands, 3508 TG
Sponsors and Collaborators
St. Antonius Hospital
Investigators
Principal Investigator: J.M.M. van den Bosch, M.D. St. Antonius Hospital
Principal Investigator: J.C. Grutters, M.D. St. Antonius Hospital
  More Information

Additional Information:
website of Heart Lung Centre Utrecht  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00267800     History of Changes
Other Study ID Numbers: R05.08/A
Study First Received: December 19, 2005
Last Updated: August 7, 2008
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by St. Antonius Hospital:
Lung disease, Interstitial
Sarcoidosis
Pulmonary fibrosis

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Fibrosis
Lung Diseases, Interstitial
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 16, 2013